EGFR and non-small cell lung carcinoma: Rociletinib (CO-1686), sharing common structural features with osimertinib, promotes tumour regression in tumour xenograft and transgenic models, and is currently being evaluated in phase I/II clinical trials in EGFR-mutant NSCLC [145].